The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia
Arza-Apalategi, S.; Heuts, B. M. H.; Bergevoet, S. M.; Meering, R.; Gilissen, D.; Jansen, P. W. T. C.; Krippner-Heidenreich, A.; Valk, P. J. M.; Vermeulen, M.; Heidenreich, O.; Haferlach, T.; Jansen, J. H.; Martens, J. H. A.; van der Reijden, B. A.
Show abstract
The KMT2A::MLLT3 fusion protein causes acute myeloid leukemia (AML) by activating the oncogenic transcription factor MECOM. However, MECOM expression occurs in only half of the KMT2A::MLLT3 cases. By integrating gene expression and enhancer activity data from patient cells, we identified neuronal homeobox transcription factor HMX3 as cell fate determining factor in MECOM-negative KMT2A::MLLT3 AML. HMX3 expression associated with younger age and KMT2A-rearranged leukemia in large AML cohorts (p<0.002). HMX3 was not expressed in other major genetic risk groups and healthy blood cells. Transcriptomic analyses revealed that HMX3 drives cancer-associated E2F, MYC and cell cycle gene programs. Ectopic HMX3 expression completely inhibited monocytic but not granulocytic colony formation of healthy CD34+ adult cells. Silencing of HMX3 in KMT2A::MLLT3 AML cell lines and patient cells resulted in cell cycle arrest, monocytic differentiation, and apoptosis. Thus, HMX3 is a leukemia-specific vulnerability that enhances proliferation and blocks differentiation of MECOM-negative KMT2A::MLLT3 leukemia.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 98%
- Mapping AML heterogeneity – multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses 97%
- Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network 97%
Similar papers in this journal
- A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML 98%
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 97%
- Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression between patients 96%
Similar papers in this journal
- Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells 98%
- Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth 98%
- Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia 96%
Similar papers in this journal
- Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes 98%
- Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities 96%
- Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications 96%
Similar papers in this journal
- Genome-wide CRISPR Screens Identify Ferroptosis as a Novel Therapeutic Vulnerability in Acute Lymphoblastic Leukemia 95%
- Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia 95%
- ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.